Skip to content
Head to head

Amylyx Pharmaceuticals vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: AMLX · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

AMLX +86.1%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
AMLXTAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price26.0221.77
Change today-0.69%+1.68%
1-year return+91.7%+57.5%
Market cap$3.35B$69.76B
52-week range10.83 – 41.1413.92 – 22.07
Valuation
P/E (TTM)-18.20311.00
P/E percentile, own 5-yr range3rd100th
P/B4.441.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-1.53-0.30
Net profit (TTM)$-196.70M$-970.94M
Revenue (TTM)$0$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+6.7%
Gross margin-42.6%65.8%
Operating margin-292.6%14.3%
Net margin-345.4%0.9%
Free cash flow (TTM)$-130.02M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership97.8%51.3%
Insider activity (12mo)22 buy / 28 sell19 buy / 31 sell
Short interest (% of float)10.2%0.1%
Analyst consensus100% buy (9)100% buy (1)
Analyst price target$46 (+78%)$50 (+132%)
StockVane view
StockVane Quant RatingC (95)C (90)
Company
Employees13647,029
Founded20131781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.